ArticleNon-coding RNA research2026
LncRNA MIR22HG and miR-10a-5p: Pioneering serum biomarkers for pancreatic cancer diagnosis and progression assessment.
Article in Non-coding RNA research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pancreatic cancer (PC) endures as one of the most lethal malignancies, characterized by a dismal prognosis due to late-stage detection and limited therapeutic options. Circulating noncoding RNAs (ncRNAs) play significant roles in malignancy detection and prognosis. Thus, we evaluated the clinical value of serum long ncRNA MIR22HG and miR-10a-5p in PC cases, clarifying their relationship with downstream targets: β-catenin, C-myc, and E-cadherin. Methods: A case-control study was conducted involving 65 PC cases and 25 healthy controls, utilizing RT-qPCR to measure serum levels of MIR22HG, miR-10a-5p, β-catenin, C-myc, and ELISA to investigate E-cadherin. Besides, CA19.9 and CEA were assessed employing the chemiluminescence approach. Results: Our findings revealed significant downregulation of MIR22HG, β-catenin, and C-myc, alongside upregulation of miR-10a-5p and E-cadherin in the serum of PC cases compared to controls. MIR22HG and miR-10a-5p demonstrated high diagnostic accuracy for PC with AUCs of 0.95 and 0.97, respectively. The diagnostic efficiency of PC traditional markers, CA19.9 or CEA, was enhanced by integrating with MIR22HG and miR-10a-5p. Moreover, low MIR22HG and β-catenin serum levels were notably associated with advanced lymphatic and distant metastases, distinguishing between metastatic and curative PC cases with AUCs of 0.73 and 0.82, respectively. MIR22HG was notably positively correlated with β-catenin and C-myc, whereas it was negatively correlated with miR-10a-5p. Conclusion: This study highlights the clinical potential of serum MIR22HG and miR-10a-5p as novel diagnostic biomarkers and identifies MIR22HG and β-catenin as prognostic indicators, thereby paving the way for improved PC management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.